137 related articles for article (PubMed ID: 37052897)
1. Risk of New Retinal Vascular Occlusion After mRNA COVID-19 Vaccination Within Aggregated Electronic Health Record Data.
Dorney I; Shaia J; Kaelber DC; Talcott KE; Singh RP
JAMA Ophthalmol; 2023 May; 141(5):441-447. PubMed ID: 37052897
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of New-Onset Tinnitus after COVID-19 Vaccination with Comparison to Other Vaccinations.
Dorney I; Bobak L; Otteson T; Kaelber DC
Laryngoscope; 2023 Jul; 133(7):1722-1725. PubMed ID: 36098476
[TBL] [Abstract][Full Text] [Related]
3. Tetanus, diphtheria, and acellular pertussis vaccination during pregnancy and reduced risk of infant acute respiratory infections.
Khodr ZG; Bukowinski AT; Gumbs GR; Conlin AMS
Vaccine; 2017 Oct; 35(42):5603-5610. PubMed ID: 28916245
[TBL] [Abstract][Full Text] [Related]
4. Association between community-level political affiliation and peripartum vaccination.
Post S; Lynch CD; Costantine MM; Fox B; Wu J; Kiefer MK; Rood KM; Landon MB; Grobman WA; Venkatesh KK
Am J Obstet Gynecol MFM; 2023 Aug; 5(8):101007. PubMed ID: 37156464
[TBL] [Abstract][Full Text] [Related]
5. Predictors of tetanus, diphtheria, acellular pertussis and influenza vaccination during pregnancy among full-term deliveries in a medically underserved population.
Doraivelu K; Boulet SL; Biswas HH; Adams JC; Haddad LB; Jamieson DJ
Vaccine; 2019 Sep; 37(41):6054-6059. PubMed ID: 31471152
[TBL] [Abstract][Full Text] [Related]
6. The Risk of Optic Neuritis following mRNA Coronavirus Disease 2019 Vaccination Compared to Coronavirus Disease 2019 Infection and Other Vaccinations.
Shukla P; Sharma N; Shaia JK; Cohen DA; Singh RP; Talcott KE
Ophthalmology; 2024 Feb; ():. PubMed ID: 38408705
[TBL] [Abstract][Full Text] [Related]
7. Association between acceptance of routine pregnancy vaccinations and COVID-19 vaccine uptake in pregnant patients.
Ha L; Levian C; Greene N; Goldfarb I; Hirsch A; Naqvi M
J Infect; 2023 Dec; 87(6):551-555. PubMed ID: 37865294
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
[TBL] [Abstract][Full Text] [Related]
9. Acceptance of Routine Vaccines in Pregnancy during the COVID-19 Pandemic.
Perelman AD; Trostle ME; Pecoriello J; Quinn GP; Roman AS; Penfield CA
Am J Perinatol; 2024 May; 41(S 01):e3059-e3064. PubMed ID: 37816391
[TBL] [Abstract][Full Text] [Related]
10. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
McCormack PL
Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
[TBL] [Abstract][Full Text] [Related]
11. Risk of abducens nerve palsy following COVID-19 vaccination.
Chauhan MZ; Eleiwa TK; Abdelnaem S; Kwok A; Hunter DG; Phillips PH; Sallam AB; Elhusseiny AM
J AAPOS; 2024 Apr; 28(2):103867. PubMed ID: 38458601
[TBL] [Abstract][Full Text] [Related]
12. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
[TBL] [Abstract][Full Text] [Related]
13. Retinal Artery and Vein Occlusion Risks after Coronavirus Disease 2019 or Coronavirus Disease 2019 Vaccination.
Park HS; Lee NK; Lee CS; Byeon SH; Kim SS; Lee SW; Kim YJ
Ophthalmology; 2024 Mar; 131(3):322-332. PubMed ID: 37739232
[TBL] [Abstract][Full Text] [Related]
14. Using the 4 Pillars™ Practice Transformation Program to increase adolescent human papillomavirus, meningococcal, tetanus-diphtheria-pertussis and influenza vaccination.
Zimmerman RK; Raviotta JM; Nowalk MP; Moehling KK; Reis EC; Humiston SG; Lin CJ
Vaccine; 2017 Oct; 35(45):6180-6186. PubMed ID: 28947346
[TBL] [Abstract][Full Text] [Related]
15. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
Weston WM; Friedland LR; Wu X; Howe B
Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
[TBL] [Abstract][Full Text] [Related]
16. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.
Halperin SA; Donovan C; Marshall GS; Pool V; Decker MD; Johnson DR; Greenberg DP;
J Pediatric Infect Dis Soc; 2019 May; 8(2):105-114. PubMed ID: 29438562
[TBL] [Abstract][Full Text] [Related]
17. Patient attitudes toward influenza and tetanus, diphtheria and acellular pertussis vaccination in pregnancy.
Strassberg ER; Power M; Schulkin J; Stark LM; Mackeen AD; Murtough KL; Paglia MJ
Vaccine; 2018 Jul; 36(30):4548-4554. PubMed ID: 29907484
[TBL] [Abstract][Full Text] [Related]
18. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
[TBL] [Abstract][Full Text] [Related]
19. Influenza, Tdap, and COVID-19 Vaccination Coverage and Hesitancy Among Pregnant Women - United States, April 2023.
Razzaghi H; Kahn KE; Calhoun K; Garacci E; Skoff TH; Ellington SR; Jatlaoui TC; Black CL
MMWR Morb Mortal Wkly Rep; 2023 Sep; 72(39):1065-1071. PubMed ID: 37768879
[TBL] [Abstract][Full Text] [Related]
20. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
